Posted on December 14th, 2010 by Health News
Vical Incorporated announced today that the company’s Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Read more
Filed under: Pharmacy News
Tags: cancer, DNA, Pharmacy, Protein
Related posts
- Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial (0)
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.
Read more
[tags] [...]
- Aurora-A protein blocks proper functioning of tumor-suppressor p73 (0)
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Read more
[tags] Pharmacy News [/tags]
- ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
Read more
[tags] Pharmacy News [/tags]
- ZIOPHARM receives European patent allowance for palifosfamide to treat cancer (0)
ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.
Read more
[tags] Pharmacy [...]
- What Protein And Where It Is Located Are Important For Drug Design (0)
Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using [...]
Leave a Reply